{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063702","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.083574+00:00","generated_at":"2026-06-08T04:21:20.262197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Heron Therapeutics raises FY2023 oncology sales guidance; projects FY2024 EBITDA breakeven","bullets":["FY2023 net product sales guidance raised to $123-125M; oncology franchise now $104-106M.","FY2024 net product sales expected $138-158M; acute care franchise growing >48% YoY.","Gross margin forecast to improve from 41% (2023) to 69% (2024) and >75% (2025+).","Q3 2023 inventory write-offs of $7.5M; one-time expenses $4.1M; loss from ops $24.9M.","ZYNRELEF expanded label PDUFA date Jan 23, 2024; VAN program PAS submission early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063702","json":"https://secwatch.observer/filing/0000950170-23-063702.json","markdown":"https://secwatch.observer/filing/0000950170-23-063702.md","text":"https://secwatch.observer/filing/0000950170-23-063702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/0000950170-23-063702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/hrtx-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:21:20.262197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f71bb836fb17451fe812597bfde5c46699dcb6e0","claim":"HERON THERAPEUTICS, INC. /DE/ updated its three and nine months ended September 30, 2023 guidance (raised).","evidence_excerpt":"On November 14, 2023, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 (“Earnings Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/0000950170-23-063702-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}